Gladstone and UCSF scientists developed a method to genetically edit myeloid cells, immune cells that act as the body's first responders.

Primary human myeloid cells are efficiently edited using virus-like particles.

An in vivo model that is able to recover human T cells from solid tumours can identify targets to help improve CAR T cell antitumour activity.